Trial Profile
The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia (CHR-2797-038).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Tosedostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms OPAL; TOPAZ
- Sponsors Chroma Therapeutics
- 04 Mar 2013 Results from the OPAL trial have been published in Lancet Oncology according to a Cell Therapeutics media release. Results were also summarised in the media release.
- 14 Feb 2012 Actual patient number changed from 73 to 76 as reported by ClinicalTrials.gov (Parent trial: NCT00780598).
- 14 Feb 2012 Actual patient number changed from 73 to 76 as reported by ClinicalTrials.gov (Parent trial: NCT00780598).